Policy and process issues resurfaced as stakeholders pushed for faster clinical-trial review timelines. A House committee directed the FDA to reform how it signs off on new INDs, reflecting concerns that the US needs to keep pace with China and other competitors. At the same time, industry compliance leaders warned that the speed of regulatory change is stressing internal governance. In particular, shifting pricing, enforcement, and tech-risk expectations are forcing compliance teams to update controls while maintaining business continuity. The combined message from Washington and from industry operations is that regulatory acceleration and regulatory complexity are converging, creating both momentum and risk for sponsors scaling trial and commercial readiness.